HEPATOCELLULAR CARCINOMA (HCC)

This large, completed study tested if a new drug called tislelizumab helps people with advanced liver cancer live longer than the standard treatment, sorafenib. It involved 684 adults whose cancer could not be removed by surgery and who had not received prior drug treatment for i…

This study tested a computer model designed to help surgeons make better decisions for patients with a complex type of liver cancer that has spread into the bile duct. The model analyzed patient scans and health data to predict who would live longer if surgeons removed the bile d…

This study tested whether adding an immunotherapy drug (pembrolizumab) to a standard tumor-destroying procedure (ablation) could better control early-stage liver cancer. It involved 30 patients eligible for ablation, aiming to see if the combination could shrink tumors before the…

This study looked back at medical records to see how well a three-part treatment worked for people with high-risk liver cancer. The treatment combined two immunotherapy drugs with a special type of chemotherapy delivered directly to the liver. Researchers analyzed data from about…

This study looked back at nearly 500 liver cancer patients who received a liver transplant. Researchers wanted to see if taking certain cancer-fighting drugs (tyrosine kinase inhibitors) before the transplant surgery helped control the cancer better. They checked if the drugs led…

This study tested a new artificial intelligence (AI) tool designed to help doctors make better treatment decisions for patients with liver cancer (hepatocellular carcinoma). The AI analyzed patient data to predict how the disease might progress and how well different treatments l…

This study tested whether adding an artificial intelligence (AI) system to a radiologist's routine could improve the detection and diagnosis of liver tumors on CT scans. Over 10,000 adults who had a specific type of liver CT scan were included. The goal was to see if the AI could…

This study looked back at 324 patients with intermediate-stage liver cancer to see if features on a standard CT scan could predict who would live longer. Researchers compared patients who received a standard procedure (TACE) plus a pill (TKI) to those who received the procedure a…